ETC
DNLI icon

Exchange Traded Concepts’s Denali Therapeutics DNLI Stock Holding History

Exchange Traded Concepts’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,584
Closed -$71.9K – 1173
2022
Q4 		$71.9K Buy
2,584
+408
+19% +$12.1K ﹤0.01% 802
2022
Q3 		$67K Buy
2,176
+302
+16% +$9.82K ﹤0.01% 794
2022
Q2 		$55K Buy
1,874
+1,382
+281% +$36.2K ﹤0.01% 899
2022
Q1 		$16K Buy
+492
New +$16.9K ﹤0.01% 1055
2021
Q2 		– Sell
-125
Closed -$7K – 1136
2021
Q1 		$7K Sell
125
-380
-75% -$25.4K ﹤0.01% 1007
2020
Q4 		$42K Buy
+505
New +$30.5K ﹤0.01% 756

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Exchange Traded Concepts's DNLI Position: Q1 2023 in Review

Exchange Traded Concepts sold out of Denali Therapeutics (DNLI) in Q1 2023, closing a stake of 2,584 shares — an estimated $71.9K sold.

Exchange Traded Concepts first reported a position in DNLI in Q4 2020 and held it in 6 quarters. The position peaked at $71.9K in Q4 2022. 202 funds tracked by Wall St. Rank hold DNLI as of Q1 2023.

  • Exchange Traded Concepts reported no remaining Denali Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Exchange Traded Concepts sold 2,584 Denali Therapeutics shares in Q1 2023, an estimated $71.9K.
  • Exchange Traded Concepts first reported a position in Denali Therapeutics in Q4 2020 and held it in 6 quarters.
  • Exchange Traded Concepts's Denali Therapeutics position peaked at $71.9K in Q4 2022.
  • 202 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2023.

Based on Exchange Traded Concepts's 13F filing for Q1 2023, filed 12 Apr 2023.